Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry
Frontiers in Pharmacology · 19.02.2025 · 16
DOI: 10.3389/fphar.2025.1462254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.02.2025. Verfasst von Antonio Vitale und 58 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Univers…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
VEXAS syndrome, a recently identified systemic autoinflammatory disorder, poses new diagnostic and management challenges. Based on experience with other autoinflammatory diseases, anti-interleukin (IL)-1, anti-IL-6, anti-tumor necrosis factor (TNF) biotechnological agents, and Janus kinase inhibitors (JAKis) have been widely employed in VEXAS patients. The aim of this study is to evaluate the global effectiveness and safety of biotechnological agents and JAKis using data from the real-world context.
Methods
Clinical, laboratory, and therapeutic data from VEXAS patients were obtained from the international AIDA Network VEXAS registry.
Results
In total, 69 VEXAS patients were enrolled in the study. Among them, 12 patients (13 treatment courses) received IL-1 inhibitors, 12 patients (13 treatment courses) were administered anti-IL-6 agents, 8 patients (9 treatment courses) were treated with anti-TNF agents, and 16 patients (17 treatment courses) were treated with JAKis. A complete response was observed in 3 patients (23%) treated with anti-IL-1 agents, 2 patients (15%) receiving IL-6 inhibitors, 1 patient (11%) receiving TNF inhibitors, and 4 patients (23.5%) treated with JAKis. The mean prednisone (or equivalent) dosage significantly decreased during anti-IL-1 treatment (p = 0.01), while glucocorticoids changed during anti-IL-6, anti-TNF, and JAKi treatment in a non-significant fashion. A total of 21 patients experienced adverse events, 3 of which led to death (gut perforation, Legionnaires’ disease, and infectious pneumonia) while on JAKis; treatment withdrawal was required for 8 out of 21 patients.
Conclusion
IL-1 and IL-6 inhibitors, along with JAKis, represent promising therapeutic options for VEXAS patients, albeit careful monitoring is mandatory to control disease activity and ensure safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.
- Autoinflammatory and Autoimmune Diseases (RITA) Center Siena, Azienda Ospedaliero-Universitaria Senese European Reference Network (ERN) for Rare Immunodeficiency, Siena, Italy.
- UOC di Reumatologia, Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Department of Ophthalmology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, SA, Australia.
Zitieren
APA
Vitale, A., Caggiano, V., Leone, F., Hinojosa-Azaola, A., Martín-Nares, E., Guaracha-Basañez, G. A., Torres-Ruiz, J., Kawakami-Campos, P. A., Hissaria, P., Callisto, A., Beecher, M., Dagna, L., Campochiaro, C., Tomelleri, A., Frassi, M., Franceschini, F., Crisafulli, F., Hernández-Rodríguez, J., Gómez-Caverzaschi, V., …, & Cantarini, L. (2025). Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1462254
Vancouver
Vitale A, Caggiano V, Leone F, Hinojosa-Azaola A, Martín-Nares E, Guaracha-Basañez GA, et al. Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1462254
BibTeX
@article{Vitale2025,
author = {Vitale, Antonio and Caggiano, Valeria and Leone, Flavia and Hinojosa-Azaola, Andrea and Martín-Nares, Eduardo and Guaracha-Basañez, Guillermo Arturo and Torres-Ruiz, Jiram and Kawakami-Campos, Perla Ayumi and Hissaria, Pravin and Callisto, Alicia and Beecher, Mark and Dagna, Lorenzo and Campochiaro, Corrado and Tomelleri, Alessandro and Frassi, Micol and Franceschini, Franco and Crisafulli, Francesca and Hernández-Rodríguez, José and Gómez-Caverzaschi, Verónica and Araújo, Olga and Sfriso, Paolo and Bindoli, Sara and Baggio, Chiara and Sota, Jurgen and Tufan, Abdurrahman and Kucuk, Hamit and Piga, Matteo and Cauli, Alberto and D'Agostino, Maria Antonietta and De Paulis, Amato and Mormile, Ilaria and Giardini, Henrique A Mayrink and Cordeiro, Rafael Alves and Lopalco, Giuseppe and Iannone, Florenzo and Monti, Sara and Montecucco, Carlomaurizio and Ruiz-Irastorza, Guillermo and Soto-Peleteiro, Adriana and Triggianese, Paola and Gurnari, Carmelo and Viapiana, Ombretta and Bixio, Riccardo and Vitetta, Rosetta and Rovera, Guido and Conticini, Edoardo and La Torre, Francesco and Portincasa, Piero and Jaber, Nour and Ragab, Gaafar and Maher, Amina and Batu, Ezgi Deniz and Ozen, Seza and Wiesik-Szewczyk, Ewa and de-la-Torre, Alejandra and Balistreri, Alberto and Frediani, Bruno and Fabiani, Claudia and Cantarini, Luca},
title = {Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1462254}
}
EUVIMED